Thymosin β4 protein therapy for cardiac repair

Current Pharmaceutical Design

Volumn 18, Issue 6, 2012, Pages 799-806

  Dubé, Karina N ^a   Bollini, Sveva ^a   Smart, Nicola ^a   Riley, Paul R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiovascular disease; Drug delivery; Paracrine effect; Regenerative medicine; Thymosin beta 4

Indexed keywords

THYMOSIN BETA4;

CELL SURVIVAL; CELL THERAPY; CELL TRANSPLANTATION; EPICARDIUM; HEART DEVELOPMENT; HEART DISEASE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; INFLAMMATION; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; REVIEW; TISSUE REGENERATION;

GENE EXPRESSION REGULATION; HEART DISEASES; HUMANS; MYOCYTES, CARDIAC; THYMOSIN;

EID: 84856468064     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799277699     Document Type: Review

References (124)

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3: e442.
2. Reinecke H, Minami E, Zhu WZ, Laflamme MA. Cardiogenic differentiation and transdifferentiation of progenitor cells. Circ Res 2008; 103: 1058-71.
3. Jameel MN, Zhang J. Heart failure management: the present and the future. Antioxid Redox Signal 2009; 11: 1989-2010.
4. Heidenreich PA, McClellan M. Trends in treatment and outcomes for acute myocardial infarction: 1975-1995. Am J Med 2001; 110: 165-74.
5. Malliaras K, Marban E. Cardiac cell therapy: where we've been, where we are, and where we should be headed. Br Med Bull 2011; 98: 161-85.
6. Limana F, Capogrossi MC, Germani A. The epicardium in cardiac repair: from the stem cell view. Pharmacol Ther 2011; 129: 82-96.
7. Kikuchi K, Holdway JE, Major RJ, et al. Retinoic acid production by endocardium and epicardium is an injury response essential for zebrafish heart regeneration. Dev Cell 2011; 20: 397-404.
8. Kim J, Wu Q, Zhang Y, et al. PDGF signaling is required for epicardial function and blood vessel formation in regenerating zebrafish hearts. Proc Natl Acad Sci USA 2010; 107: 17206-10.
9. Schnabel K, Wu CC, Kurth T, Weidinger G. Regeneration of cryoinjury induced necrotic heart lesions in zebrafish is associated with epicardial activation and cardiomyocyte proliferation. PLoS One 2011; 6: e18503.
10. Mummery CL, Davis RP, Krieger JE. Challenges in using stem cells for cardiac repair. Sci Transl Med 2010; 2: 27ps17.
11. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410: 701-5.
12. Mummery C, Ward D, van den Brink CE, et al. Cardiomyocyte differentiation of mouse and human embryonic stem cells. J Anat 2002; 200: 233-42.
13. Menasche P. Skeletal myoblasts as a therapeutic agent. Prog Cardiovasc Dis 2007; 50: 7-17.
14. Narazaki G, Uosaki H, Teranishi M, et al. Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation 2008; 118: 498-506.
15. Mauritz C, Schwanke K, Reppel M, et al. Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation 2008; 118: 507-17.
16. Guan K, Wagner S, Unsold B, et al. Generation of functional cardiomyocytes from adult mouse spermatogonial stem cells. Circ Res 2007; 100: 1615-25.
17. Schachinger V, Assmus B, Honold J, et al. Normalization of coronary blood flow in the infarct-related artery after intracoronary progenitor cell therapy: intracoronary Doppler substudy of the TOPCARE-AMI trial. Clin Res Cardiol 2006; 95: 13-22.
18. Yen BL, Huang HI, Chien CC, et al. Isolation of multipotent cells from human term placenta. Stem Cells 2005; 23: 3-9.
19. Kadner A, Zund G, Maurus C, et al. Human umbilical cord cells for cardiovascular tissue engineering: a comparative study. Eur J Cardiothorac Surg 2004; 25: 635-41.
20. Schmidt D, Breymann C, Weber A, et al. Umbilical cord blood derived endothelial progenitor cells for tissue engineering of vascular grafts. Ann Thorac Surg 2004; 78: 2094-8.
21. Bollini S, Pozzobon M, Nobles M, et al. In vitro and in vivo cardiomyogenic differentiation of amniotic fluid stem cells. Stem Cell Rev 2011; 7: 364-80.
22. Bollini S, Cheung KK, Riegler J, et al. Amniotic fluid stem cells are cardioprotective following acute myocardial infarction. Stem Cells Dev 2011;
23. Gersh BJ, Simari RD, Behfar A, Terzic CM, Terzic A. Cardiac cell repair therapy: a clinical perspective. Mayo Clin Proc 2009; 84: 876-92.
24. Mirotsou M, Jayawardena TM, Schmeckpeper J, Gnecchi M, Dzau VJ. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. J Mol Cell Cardiol 2011; 50: 280-9.
25. Maltais S, Tremblay JP, Perrault LP, Ly HQ. The paracrine effect: pivotal mechanism in cell-based cardiac repair. J Cardiovasc Transl Res 2010; 3: 652-62.
26. Harrison RG. The regenerative capacity of cardiac muscle. J Anat 1947; 81: 365-6.
27. King ES. REGENERATION IN CARDIAC MUSCLE. Br Heart J 1940; 2: 155-64.
28. Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science 2009; 324: 98-102.
29. Bollini S, Smart N, Riley PR. Resident cardiac progenitor cells: at the heart of regeneration. J Mol Cell Cardiol 2011; 50: 296-303.
30. Smart N, Bollini S, Dube KN, et al. De novo cardiomyocytes from within the activated adult heart after injury. Nature 2011;
31. Urbanek K, Rota M, Cascapera S, et al. Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and longterm survival. Circ Res 2005; 97: 663-73.
32. Rota M, Padin-Iruegas ME, Misao Y, et al. Local activation or implantation of cardiac progenitor cells rescues scarred infarcted myocardium improving cardiac function. Circ Res 2008; 103: 107-16.
33. Rosenblatt-Velin N, Lepore MG, Cartoni C, Beermann F, Pedrazzini T. FGF-2 controls the differentiation of resident cardiac precursors into functional cardiomyocytes. J Clin Invest 2005; 115: 1724-33.
34. Pesce M, Burba I, Gambini E, et al. Endothelial and cardiac progenitors: boosting, conditioning and (re)programming for cardiovascular repair. Pharmacol Ther 2011; 129: 50-61.
35. Mouquet F, Pfister O, Jain M, et al. Restoration of cardiac progenitor cells after myocardial infarction by self-proliferation and selective homing of bone marrow-derived stem cells. Circ Res 2005; 97: 1090-2.
36. Nakanishi C, Yamagishi M, Yamahara K, et al. Activation of cardiac progenitor cells through paracrine effects of mesenchymal stem cells. Biochem Biophys Res Commun 2008; 374: 11-6.
37. Loffredo FS, Steinhauser ML, Gannon J, Lee RT. Bone marrowderived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. Cell Stem Cell 2011; 8: 389-98.
38. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008; 103: 1204-19.
39. Burchfield JS, Dimmeler S. Role of paracrine factors in stem and progenitor cell mediated cardiac repair and tissue fibrosis. Fibrogenesis Tissue Repair 2008; 1: 4.
40. Stastna M, Abraham MR, Van Eyk JE. Cardiac stem/progenitor cells, secreted proteins, and proteomics. FEBS Lett 2009; 583: 1800-7.
41. Lam JT, Moretti A, Laugwitz KL. Multipotent progenitor cells in regenerative cardiovascular medicine. Pediatr Cardiol 2009; 30: 690-8.
42. Gittenberger-de Groot AC, Winter EM, Poelmann RE. Epicardiumderived cells (EPDCs) in development, cardiac disease and repair of ischemia. J Cell Mol Med 2010; 14: 1056-60.
43. Chen TH, Chang TC, Kang JO, et al. Epicardial induction of fetal cardiomyocyte proliferation via a retinoic acid-inducible trophic factor. Dev Biol 2002; 250: 198-207.
44. Zhou B, Honor LB, He H, et al. Adult mouse epicardium modulates myocardial injury by secreting paracrine factors. J Clin Invest 2011; 121: 1894-904.
45. Bock-Marquette I, Shrivastava S, Pipes GC, et al. Thymosin beta4 mediated PKC activation is essential to initiate the embryonic coronary developmental program and epicardial progenitor cell activation in adult mice in vivo. J Mol Cell Cardiol 2009; 46: 728-38.
46. Smart N, Dube KN, Riley PR. Coronary vessel development and insight towards neovascular therapy. Int J Exp Pathol 2009; 90: 262-83.
47. Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J 2010; 24: 2144-51.
48. Hannappel E. Thymosin beta4 and its posttranslational modifications. Ann N Y Acad Sci 2010; 1194: 27-35.
49. Hinkel R, Bock-Marquette I, Hatzopoulos AK, Kupatt C. Thymosin beta4: a key factor for protective effects of eEPCs in acute and chronic ischemia. Ann N Y Acad Sci 2010; 1194: 105-11.
50. Hinkel R, El-Aouni C, Olson T, et al. Thymosin beta4 is an essential paracrine factor of embryonic endothelial progenitor cellmediated cardioprotection. Circulation 2008; 117: 2232-40.
51. Huang WQ, Wang QR. Bone marrow endothelial cells secrete thymosin beta4 and AcSDKP. Exp Hematol 2001; 29: 12-8.
52. Hooper JA, McDaniel MC, Thurman GB, et al. Purification and properties of bovine thymosin. Ann N Y Acad Sci 1975; 249: 125-44.
53. Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci USA 1981; 78: 1162-6.
54. Huff T, Muller CS, Otto AM, Netzker R, Hannappel E. beta- Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol 2001; 33: 205-20.
55. Sanders MC, Goldstein AL, Wang YL. Thymosin beta 4 (Fx peptide) is a potent regulator of actin polymerization in living cells. Proc Natl Acad Sci USA 1992; 89: 4678-82.
56. Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem 1991; 266: 4029-32.
57. Malinda KM, Goldstein AL, Kleinman HK. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J 1997; 11: 474-81.
58. Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature 2007; 445: 177-82.
59. Philp D, St-Surin S, Cha HJ, et al. Thymosin beta 4 induces hair growth via stem cell migration and differentiation. Ann N Y Acad Sci 2007; 1112: 95-103.
60. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004; 432: 466-72.
61. Huang WQ, Wang BH, Wang QR. Thymosin beta4 and AcSDKP inhibit the proliferation of HL-60 cells and induce their differentiation and apoptosis. Cell Biol Int 2006; 30: 514-20.
62. Sosne G, Siddiqi A, Kurpakus-Wheater M. Thymosin-beta4 inhibits corneal epithelial cell apoptosis after ethanol exposure in vitro. Invest Ophthalmol Vis Sci 2004; 45: 1095-100.
63. Tapp H, Deepe R, Ingram JA, et al. Exogenous thymosin beta4 prevents apoptosis in human intervertebral annulus cells in vitro. Biotech Histochem 2009; 84: 287-94.
64. Yang H, Cui GB, Jiao XY, et al. Thymosin-beta4 attenuates ethanol-induced neurotoxicity in cultured cerebral cortical astrocytes by inhibiting apoptosis. Cell Mol Neurobiol 2010; 30: 149-60.
65. Zhao Y, Qiu F, Xu S, Yu L, Fu G. Thymosin beta4 activates integrin-linked kinase and decreases endothelial progenitor cells apoptosis under serum deprivation. J Cell Physiol 2010;
66. Sosne G, Szliter EA, Barrett R, et al. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res 2002; 74: 293-9.
67. Philp D, Goldstein AL, Kleinman HK. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev 2004; 125: 113-5.
68. Grant DS, Rose W, Yaen C, et al. Thymosin beta4 enhances endothelial cell differentiation and angiogenesis. Angiogenesis 1999; 3: 125-35.
69. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol 1999; 113: 364-8.
70. Sosne G, Chan CC, Thai K, et al. Thymosin beta 4 promotes corneal wound healing and modulates inflammatory mediators in vivo. Exp Eye Res 2001; 72: 605-8.
71. Huff T, Rosorius O, Otto AM, et al. Nuclear localisation of the Gactin sequestering peptide thymosin beta4. J Cell Sci 2004; 117: 5333-41.
72. Smart N, Rossdeutsch A, Riley PR. Thymosin beta4 and angiogenesis: modes of action and therapeutic potential. Angiogenesis 2007; 10: 229-41.
73. Brieger A, Adryan B, Wolpert F, et al. Cytoskeletal scaffolding proteins interact with Lynch-Syndrome associated mismatch repair protein MLH1. Proteomics 2010; 10: 3343-55.
74. Brieger A, Plotz G, Zeuzem S, Trojan J. Thymosin beta 4 expression and nuclear transport are regulated by hMLH1. Biochem Biophys Res Commun 2007; 364: 731-6.
75. Bednarek R, Boncela J, Smolarczyk K, et al. Ku80 as a novel receptor for thymosin beta4 that mediates its intracellular activity different from G-actin sequestering. J Biol Chem 2008; 283: 1534-44.
76. Freeman KW, Bowman BR, Zetter BR. Regenerative protein thymosin beta-4 is a novel regulator of purinergic signaling. FASEB J 2011; 25: 907-15.
77. Feoktistov I, Biaggioni I, Cronstein BN. Adenosine receptors in wound healing, fibrosis and angiogenesis. Handb Exp Pharmacol 2009; 193: 383-97.
78. Lee SJ, So IS, Park SY, Kim IS. Thymosin beta4 is involved in stabilin-2-mediated apoptotic cell engulfment. FEBS Lett 2008; 582: 2161-6.
79. Grillon C, Rieger K, Bakala J, et al. Involvement of thymosin beta 4 and endoproteinase Asp-N in the biosynthesis of the tetrapeptide AcSerAspLysPro a regulator of the hematopoietic system. FEBS Lett 1990; 274: 30-4.
80. Smart N, Risebro CA, Melville AA, et al. Thymosin beta-4 is essential for coronary vessel development and promotes neovascularization via adult epicardium. Ann N Y Acad Sci 2007; 1112: 171-88.
81. Young JD, Lawrence AJ, MacLean AG, et al. Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids. Nat Med 1999; 5: 1424-7.
82. Gomez-Marquez J, Franco del AF, Carpintero P, Anadon R. High levels of mouse thymosin beta4 mRNA in differentiating P19 embryonic cells and during development of cardiovascular tissues. Biochim Biophys Acta 1996; 1306: 187-93.
83. Cavasin MA, Liao TD, Yang XP, Yang JJ, Carretero OA. Decreased endogenous levels of Ac-SDKP promote organ fibrosis. Hypertension 2007; 50: 130-6.
84. Chen YW, Liu BW, Zhang YJ, et al. Preservation of basal AcSDKP attenuates carbon tetrachloride-induced fibrosis in the rat liver. J Hepatol 2010; 53: 528-36.
85. Srivastava D, Saxena A, Michael DJ, Bock-Marquette I. Thymosin beta4 is cardioprotective after myocardial infarction. Ann N Y Acad Sci 2007; 1112: 161-70.
86. Smart N, Risebro CA, Clark JE, et al. Thymosin beta4 facilitates epicardial neovascularization of the injured adult heart. Ann N Y Acad Sci 2010; 1194: 97-104.
87. Cavasin MA. Therapeutic potential of thymosin-beta4 and its derivative N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) in cardiac healing after infarction. Am J Cardiovasc Drugs 2006; 6: 305-11.
88. Sosne G, Albeiruti AR, Hollis B, et al. Thymosin beta4 inhibits benzalkonium chloride-mediated apoptosis in corneal and conjunctival epithelial cells in vitro. Exp Eye Res 2006; 83: 502-7.
89. Zhou B, Ma Q, Rajagopal S, et al. Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart. Nature 2008; 454: 109-13.
90. Philp D, Nguyen M, Scheremeta B, et al. Thymosin beta4 increases hair growth by activation of hair follicle stem cells. FASEB J 2004; 18: 385-7.
91. Mollinari C, Ricci-Vitiani L, Pieri M, et al. Downregulation of thymosin beta4 in neural progenitor grafts promotes spinal cord regeneration. J Cell Sci 2009; 122: 4195-207.
92. Tokura Y, Nakayama Y, Fukada SI, et al. Muscle injury-induced thymosin {beta}4 acts as a chemoattractant for myoblasts. J Biochem 2010;
93. Porrello ER, Mahmoud AI, Simpson E, et al. Transient regenerative potential of the neonatal mouse heart. Science 2011; 331: 1078-80.
94. Poss KD, Wilson LG, Keating MT. Heart regeneration in zebrafish. Science 2002; 298: 2188-90.
95. Lepilina A, Coon AN, Kikuchi K, et al. A dynamic epicardial injury response supports progenitor cell activity during zebrafish heart regeneration. Cell 2006; 127: 607-19.
96. Kikuchi K, Holdway JE, Werdich AA, et al. Primary contribution to zebrafish heart regeneration by gata4(+) cardiomyocytes. Nature 2010; 464: 601-5.
97. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000; 101: 2981-8.
98. Frangogiannis NG. Targeting the inflammatory response in healing myocardial infarcts. Curr Med Chem 2006; 13: 1877-93.
99. Frohm M, Gunne H, Bergman AC, et al. Biochemical and antibacterial analysis of human wound and blister fluid. Eur J Biochem 1996; 237: 86-92.
100. Girardi M, Sherling MA, Filler RB, et al. Anti-inflammatory effects in the skin of thymosin-beta4 splice-variants. Immunology 2003; 109: 1-7.
101. Badamchian M, Fagarasan MO, Danner RL, et al. Thymosin beta(4) reduces lethality and down-regulates inflammatory mediators in endotoxin-induced septic shock. Int Immunopharmacol 2003; 3: 1225-33.
102. Zhang J, Zhang ZG, Morris D, et al. Neurological functional recovery after thymosin beta4 treatment in mice with experimental auto encephalomyelitis. Neuroscience 2009; 164: 1887-93.
103. Sosne G, Qiu P, Christopherson PL, Wheater MK. Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway. Exp Eye Res 2007; 84: 663-9.
104. Sopko N, Qin Y, Finan A, et al. Significance of Thymosin beta4 and Implication of PINCH-1-ILK-alpha-Parvin (PIP) Complex in Human Dilated Cardiomyopathy. PLoS One 2011; 6: e20184.
105. Qiu P, Wheater MK, Qiu Y, Sosne G. Thymosin {beta}4 inhibits TNF-{alpha}-induced NF-{kappa}B activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILK. FASEB J 2011; 25: 1815-26.
106. Philp D, Scheremeta B, Sibliss K, et al. Thymosin beta4 promotes matrix metalloproteinase expression during wound repair. J Cell Physiol 2006; 208: 195-200.
107. Peng H, Carretero OA, Raij L, et al. Antifibrotic effects of Nacetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats. Hypertension 2001; 37: 794-800.
108. Peng H, Carretero OA, Peterson EL, Rhaleb NE. Ac-SDKP inhibits transforming growth factor-beta1-induced differentiation of human cardiac fibroblasts into myofibroblasts. Am J Physiol Heart Circ Physiol 2010; 298: H1357-H1364.
109. Yang F, Yang XP, Liu YH, et al. Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction. Hypertension 2004; 43: 229-36.
110. Gnecchi M, He H, Noiseux N, et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 2006; 20: 661-9.
111. Sy JC, Davis ME. Delivering regenerative cues to the heart: cardiac drug delivery by microspheres and peptide nanofibers. J Cardiovasc Transl Res 2010; 3: 461-8.
112. Fujita M, Ishihara M, Morimoto Y, et al. Efficacy of photocrosslinkable chitosan hydrogel containing fibroblast growth factor- 2 in a rabbit model of chronic myocardial infarction. J Surg Res 2005; 126: 27-33.
113. Lin CC, Anseth KS. PEG hydrogels for the controlled release of biomolecules in regenerative medicine. Pharm Res 2009; 26: 631-43.
114. Lee J, Tan CY, Lee SK, Kim YH, Lee KY. Controlled delivery of heat shock protein using an injectable microsphere/hydrogel combination system for the treatment of myocardial infarction. J Control Release 2009; 137: 196-202.
115. Seshadri G, Sy JC, Brown M, et al. The delivery of superoxide dismutase encapsulated in polyketal microparticles to rat myocardium and protection from myocardial ischemia-reperfusion injury. Biomaterials 2010; 31: 1372-9.
116. Sy JC, Seshadri G, Yang SC, et al. Sustained release of a p38 inhibitor from non-inflammatory microspheres inhibits cardiac dysfunction. Nat Mater 2008; 7: 863-8.
117. Kraehenbuehl TP, Ferreira LS, Zammaretti P, Hubbell JA, Langer R. Cell-responsive hydrogel for encapsulation of vascular cells. Biomaterials 2009; 30: 4318-24.
118. Kraehenbuehl TP, Ferreira LS, Hayward AM, et al. Human embryonic stem cell-derived microvascular grafts for cardiac tissue preservation after myocardial infarction. Biomaterials 2011; 32: 1102-9.
119. Chiu LL, Radisic M. Controlled release of thymosin beta4 using collagen-chitosan composite hydrogels promotes epicardial cell migration and angiogenesis. J Control Release 2011;
120. Crockford D. Development of thymosin beta4 for treatment of patients with ischemic heart disease. Ann N Y Acad Sci 2007; 1112: 385-95.
121. Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci 2010; 1194: 179-89.
122. Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebocontrolled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci 2010; 1194: 223-9.
123. Lin CX, Rhaleb NE, Yang XP, et al. Prevention of aortic fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol 2008; 295: H1253-H1261.
124. Castoldi G, di Gioia CR, Bombardi C, et al. Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats. Clin Sci (Lond) 2010; 118: 211-20.